Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Halozyme to $48 from $46 and keeps an Overweight rating on the shares post the Q2 report. The company’s revenue beat and fiscal 2023 guidance was raised at the low end, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO:
- Halozyme price target lowered to $60 from $61 at H.C. Wainwright
- Halozyme raises FY23 non-GAAP EPS view to $2.65-$2.75 from $2.50-$2.65
- Halozyme reports Q2 non-GAAP EPS 74c, consensus 63c
- HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
- HALO Upcoming Earnings Report: What to Expect?